David Sumerauer

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Medulloblastomics revisited: biological and clinical insights from thousands of patients

18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

Role of Functional Imaging in the Management of Lymphoma

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

Epistasis and immunity: the role of genetic interactions in autoimmune diseases

Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations

Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease

Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations

Differential patterns of metastatic dissemination across medulloblastoma subgroups

Skin Lesions in a Boy With X-linked Lymphoproliferative Disorder: Comparison of 5 SH2D1A Deletion Cases